Patients with asthma who did require hospitalization for SARS-CoV-2 infection were at greater risk for intubation and remdesivir treatment, a new study reports.
Asthma was not associated with increased risk of hospitalization for COVID-19 but patients with asthma who were hospitalized were at risk for more severe disease, in findings from a new study by researchers from Kaiser Permanente (KP) Northern California.
Specifically, asthma patients hospitalized for COVID-19 were at increased risk for ICU admission, intubation, and treatment with remdesivir.
The study results are being presented at the American Association of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting, held in Phoenix, Arizona, from February 25 to 28.
Citing the limited knowledge about asthma as a risk factor for COIVD-19, the KP investigators conducted a retrospective cohort study that compared the incidence of COVID-19 infection, hospitalization, and severity of COVID-19 during 2020 in a large group (n = 41,282) of adult patients with asthma and a control group of the same size matched for age, sex, and race/ethnicity. Mean age of the combined cohorts was 55 years; 63% were female, and 55% were White. The researchers used electronic health records to collect data on demographics, clinical factors, comorbidities, polymerase chain reaction COVID-19 testing, hospitalization, and inpatient COVID-19 treatment.
After multivariable adjustment investigators found that asthma was inversely associated with having a positive COVID-19 test (8.7 vs 9.4% positive among those tested; OR=0.90; 95% CI, 0.82-0.99; p=0.03). Specific adjustments were for age, sex, race/ethnicity, BMI, smoking, Neighborhood Deprivation Index, and comorbidities.
After adjusting for the same covariates in each instance, Asthma was not associated with COVID-19 hospitalization (2.9 vs 1.4 per 1,000 persons; OR=1.04; 95% CI, 0.96-1.12; p 0.32) but having asthma was positively associated with a composite outcome of COVID-19-related ICU admission, intubation, or remdesivir treatment (2.5 vs 1.0 per 1,000 persons; OR=1.89; 95% CI, 1.28-2.81; p=0.001).
Based on these results the authors conclude that “asthma may be a risk factor for severe COVID-19” even though in this analysis it was associated with lower odds of virus infection and not independently associated with risk for hospitalization.
Reference: Finkas LK, Block L, Lu M, et al. Retrospective analysis of COVID-19 incidence and health outcomes among patients with asthma in a large integrated health care delivery system. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting; February 25–28, 2022; Phoenix, AZ. Abstract 171.
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16th 2025The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.